Unlocking Insights from Tender or RFP Data

Tender data contains a wealth of information that can inform various aspects of a MedTech company’s GTM strategy. Some of the key insights that can be gleaned from tender documents include:

1. Product Availability: Tender notices and documents often specify the types of products required, along with their technical specifications and desired features. This information can help MedTech companies understand the range of products available in the market and identify gaps or opportunities for innovation.

2. Supplier Landscape: Tender award notifications reveal the successful bidders, providing insights into the competitive landscape. By analysing this information, MedTech companies can identify their key competitors, assess their market share, track price movements, and monitor their activities.

3. Pricing and Discounts: In many markets, tender documents disclose the prices and discounts offered by suppliers. This transparency allows MedTech companies to benchmark their pricing strategies, understand the price sensitivity of buyers, and identify opportunities for competitive positioning.

4. Buyer Preferences: Tender documents often outline the evaluation criteria used by buyers to assess bids. These criteria may include factors such as product quality, after-sales support, training, and sustainability. By understanding buyer preferences, MedTech companies can tailor their offerings and value propositions to better meet customer needs.

5. Market Conditions: Tender data can provide insights into market-specific conditions, such as regulatory requirements, local content requirements, and payment terms. This information is crucial for MedTech companies looking to enter new markets or expand their presence in existing ones.

6. Non-Price Factors: In addition to price, tender documents may specify non-price factors that influence the award decision, such as technical capabilities, clinical evidence, and supplier reputation. MedTech companies can use this information to differentiate themselves and highlight their unique strengths.

The Tender or the RFP Landscape

Tendering is a highly regulated process that aims to ensure fair competition, transparency, and value for money in public procurement. Governments and healthcare institutions issue tenders to invite suppliers to submit bids for the provision of goods or services. The tender process typically involves several stages:

1. Tender Announcement: The buyer publishes a notice outlining their requirements, specifications, and timeline for the procurement process.

2. Tender Documents: Interested suppliers can obtain detailed tender documents that provide further information on the scope of work, evaluation criteria, and submission requirements.

3. Bid Submission: Suppliers prepare and submit their bids, which include technical and commercial proposals, as well as supporting documentation.

4. Bid Evaluation: The buyer evaluates the submitted bids based on predefined criteria, which may include price, quality, technical capabilities, and other factors.

5. Award Notification: The buyer announces the winning bidder and provides feedback to unsuccessful participants.

6. Award Documents: The buyer and the winning supplier sign a contract outlining the terms and conditions of the agreement.

Throughout this process, a significant amount of information is generated and made available to the public or semi-public, albeit for a limited time. This information can provide invaluable insights into the competitive landscape, market trends, and customer needs.

Introduction

In the highly competitive and regulated world of medical technology “MedTech”, crafting a compelling GTM strategy is crucial for success. While the United States market relies heavily on direct sales and GPO-level negotiations, the majority of the global market operates through the tender channel (also referred to as Request For Proposals “RFPs”).

Tender notices (pre-tender and post-tender), documents, award notifications, and award documents contain a wealth of valuable information that can inform and shape a MedTech company’s GTM strategy. By systematically analysing this data, sales, marketing, market access, commercial, and pricing teams can gain insights into market dynamics, competitor activities, pricing trends, and buyer preferences. However, the process of extracting, organising, and integrating this information can be challenging due to its semi-structured and unstructured nature, limited public availability, and the need to merge it with internal datasets.

This article will explore the importance of tender data in developing a robust GTM strategy for MedTech products and provide guidance on how to effectively utilise this information to drive success in institutional markets.

Challenges in Extracting and Utilising Tender Data

While tender/ RFP documents offer immense value, extracting and utilising this information can be challenging for several reasons:

1. Semi-Structured and Unstructured Data: Tender documents are often in the form of PDFs, Word documents, or HTML pages, which contain a mix of structured and unstructured data. Extracting relevant information from these sources requires advanced data parsing and natural language processing techniques.

2. Limited Public Availability: Tender notices and documents are typically available in the public domain for a limited period, often ranging from a few weeks to a month. This short window poses challenges for teams trying to collect and analyse the data manually.

3. Data Integration: To derive maximum value from tender data, it needs to be integrated with internal sales, pricing, and market intelligence datasets. This integration allows for the identification of patterns, trends, and correlations across markets and product segments. However, merging disparate data sources can be complex and time-consuming.

4. Language and Localisation: Tenders are often published in local languages and may use country-specific terminology and formats. MedTech companies operating in multiple geographies need to overcome language barriers and ensure consistent data interpretation across markets.

Leveraging Technology for Tender Data Analysis

To address the challenges of extracting and utilising tender data, MedTech companies can leverage advanced technologies such as:

1. Web Scraping: Automated web scraping tools can systematically extract tender data from online portals, websites, and databases. These tools can handle large volumes of data and navigate complex website structures to capture relevant information.

2. Optical Character Recognition “OCR”: OCR technology can convert scanned tender documents and images into machine-readable text, enabling the extraction of structured data from unstructured sources.

3. Natural Language Processing “NLP”: NLP algorithms can analyse the text in tender documents to identify key information such as product specifications, evaluation criteria, and price points. NLP can also help in language translation and localisation.

4. Data Orchestration Platforms: Specialised data integration platforms can streamline the process of merging tender data with internal datasets. These platforms can handle data cleansing, standardisation, and harmonisation, ensuring a consistent and reliable data foundation for analysis.

Applying Tender Insights to GTM Strategies

Once the tender data has been extracted and integrated, MedTech companies can use the insights to inform and optimise their GTM strategies across the four key dimensions of pricing, positioning, place, and promotion.

1. Pricing: Tender data provides visibility into the pricing strategies of competitors and the price sensitivity of buyers. MedTech companies can use net price information to develop competitive pricing models, offer targeted discounts, and negotiate more effectively with procurement teams.

2. Positioning: By analysing tender evaluation criteria and buyer preferences, MedTech companies can refine their product positioning and value propositions. This may involve highlighting unique product features, emphasising clinical benefits, or showcasing after-sales support capabilities to differentiate from competitors.

3. Place: Tender data can reveal market-specific requirements and conditions that impact the distribution and logistics of MedTech products. Companies can use this information to optimise their supply chain, establish local partnerships, and ensure compliance with regulations.

4. Promotion: Tender notices and award notifications provide insights into the decision-makers and influencers involved in the procurement process. MedTech companies can leverage this information to tailor their promotional activities, such as targeted marketing campaigns, key opinion leader engagement, and educational initiatives.

In addition to the four Ps, tender data can also shed light on the regulatory landscape and its impact on institutional markets. By monitoring tender requirements and specifications, MedTech companies can stay abreast of evolving regulations, standards, and certifications. This knowledge can help companies proactively adapt their products and processes to meet changing market demands.

Conclusion

Tender data represents a goldmine of insights for MedTech companies looking to develop effective GTM strategies in institutional markets. By systematically analysing tender notices, documents, award notifications, and award documents, companies can gain a deep understanding of market dynamics, competitor activities, pricing trends, and buyer preferences.

However, extracting and utilising tender data poses significant challenges due to its semi-structured and unstructured nature, limited public availability, and the need for data integration. To overcome these challenges, MedTech companies must leverage advanced technologies such as web scraping, OCR, NLP, and data integration platforms.

By applying the insights derived from tender data to the four key dimensions of pricing, positioning, place, and promotion, MedTech companies can create compelling GTM strategies that resonate with customers, differentiate from competitors, and drive market success. Additionally, monitoring the regulatory landscape through tender data can help companies stay compliant and adapt to changing market requirements.

In conclusion, MedTech companies that invest in the systematic analysis of tender data and integrate the insights into their GTM strategies will be well-positioned to navigate the complexities of institutional markets, drive growth, and achieve a sustainable competitive advantage.

Vamstar

Vamstar can play a crucial role in enhancing the effectiveness of a MedTech company’s GTM strategy by addressing the challenges associated with extracting, analysing, and utilising tender data at scale and asynchronously. By leveraging advanced technologies such as web scraping, OCR, NLP, Machine Learning and data integration, Vamstar can automate the process of collecting and organising tender information from various sources, including all internal datasets from CRM, Price/Revenue Management Systems or ERP systems. This not only saves time and resources but also ensures a comprehensive and up-to-date dataset that can be easily accessed and analysed by different teams within the organisation.

Moreover, Vamstar’s platform can provide a centralised repository for tender data, enabling seamless integration with internal sales, pricing, and market intelligence systems. This integration allows for the identification of patterns, trends, and correlations across markets and product segments, empowering MedTech companies to make data-driven decisions and adapt their GTM strategies in real-time. By leveraging the insights derived from Vamstar’s platform, MedTech companies can optimise their pricing models, refine product positioning, streamline distribution channels, and tailor promotional activities to better meet the needs of their target customers and stay ahead of the competition.

Business Challenges

Medical supplies include a wide range of products, from surgical instruments to bandages, that are used in healthcare facilities. Properly classifying and assigning codes to these medical supplies is critical for sourcing, tracking, billing, ordering, inventory management, and patient safety.

Key challenges include the high cost of healthcare supply-chain transactions (up to 4x higher compared to other industries), significant waste incurred e.g. $5Bn worth of COVID-19 PPE deemed ‘unusable’. In addition globally, 10% to 34% of health care spendings of OCED countries were wasted on inappropriate care.

What classifications are we talking about?

We have broken down the challenge into code-to-code, code-to-product, product-to-product, product-to-evidence, and product-to-opportunity. More specifically

• Code-to-code: suppose you have one code such as CPV and you want to match this to your own internal code or other codes such as UNSPSC.
• Code-to-product: imagine as a buyer you onboard a new supplier with 30,000 items or items that you need to assign categories to. As a supplier I need to filter or assign buyer code to my products.
• Product-to-product: as a buyer I have lots of products in my basket of goods, of different brands or suppliers, how can you compare the products to find similar ones? As a supplier how can I understand the market landscape.
• Product-to-evidence: now as a buyer you want to screen the clinical evidence of many items, how do you do this at the moment? as a supplier I want to see what my competitors are doing
• Product-to-opportunity: as a buyer I want to see the supplier products, or as a supplier I want to see the opportunities I can participate in or my competitors are doing

Why is this so complex?

Here is a selection of complexities involved in classification:

• Complexity, Diversity, and Standardisation Issues: The sheer variety of medical supplies, each with its unique specifications, makes classification intricate. Differentiating between products with minor variations can be challenging. There may be a lack of standardised naming conventions and categorisations for medical supplies, especially across different manufacturers or countries. Different vendors might use different names, codes, or specifications for similar products, making it challenging to maintain a standardised classification.
• Continuous Evolution of Products: As medical technology advances, new products are constantly introduced to the market. Keeping classification systems up-to-date becomes an ongoing task.
• Overlapping Categories: Some medical supplies can fit into multiple categories, leading to confusion about proper classification.
• Human Errors, Scale and Skill: Mistakes can occur in manual entry or categorisation processes, leading to misclassifications. Staff needs to be trained to understand and use the classification system correctly, and this training has to be updated as the system evolves.
• Regulatory and Compliance Requirements: Different regions or countries might have different regulations concerning medical supplies, which can affect how they need to be classified or coded. In multinational settings, translation and localisation can introduce further complexity to classification.
• Interoperability and Integration: Different systems within a healthcare facility, like billing, electronic health records, and inventory management, need to communicate seamlessly. Discrepancies in code classifications can lead to issues in this integration. Legacy systems in hospitals or facilities might still rely on outdated classification systems, leading to discrepancies when integrating with newer systems or vendors. Classification systems need to be compatible with inventory management systems to ensure seamless tracking of medical supplies usage and restocking needs.

Addressing these challenges requires a combination of technology, training, and careful planning. Solutions might include investing in modern inventory management systems, providing ongoing staff training, collaborating with vendors for standardisation, and regularly reviewing and updating classification systems. Doing this manually globally for all healthcare products and services is not possible and this needs an automated tracking and monitoring solution, luckily with the emergence of big data, generative AI, and graph analytics this is possible.

Following recent discussions on the NHS’s efforts to adopt a value-based procurement (VBP) methodology, it’s clear there is room for reflection and concerted action. As noted by Chris Whitehouse , a month has passed since the announcement of a new VBP approach, which aims to place greater emphasis on patient outcomes and experiences in purchasing decisions. However, the comprehensive toolkit to guide this methodology is still pending release. This delay presents a challenge to improving the NHS’s procurement efficiency, an issue that has led to considerable financial implications under the current system.

The proposed VBP methodology represents a significant shift towards prioritising the overall value that products and services provide to patient care, moving away from a focus solely on cost. This approach is designed to enhance healthcare delivery throughout England by ensuring that procurement decisions directly support patient care and contribute to system-wide efficiency.

Transitioning to a VBP model, however, has encountered some hurdles due to existing procurement practices within the NHS, which have historically emphasised cost over value. This has impacted potential savings and the quality of patient care, as seen in the procurement of absorbent continence products. Despite evidence supporting a value-based approach, traditional procurement practices have not always aligned with optimal patient experiences and outcomes.

The delay in rolling out VBP highlights the importance of ongoing commitment to innovation and patient-focused care within the NHS. Given the broad political support for VBP, addressing these challenges is critical for enhancing healthcare procurement and delivery.

Vamstar suggests a strategic revision of NHS procurement practices through the use of healthcare procurement technologies supported by artificial intelligence. By employing advanced data analytics and market intelligence, the NHS can make more informed decisions that adhere to VBP principles. This strategy includes utilising predictive analytics for assessing the long-term impact of procurement choices, incorporating patient feedback into procurement decisions, and building relationships with suppliers dedicated to innovation and quality.

Furthermore, the NHS should foster a culture of innovation within its procurement teams, encouraging purchasing managers to value overall impact over immediate cost savings and to consider the effects of decisions on patient care and the sustainability of the health system.

Vamstar is committed to enriching the knowledge of healthcare procurers by introducing a content-rich platform focused on exploring innovative procurement methodologies and the advantages of advanced data analytics.

The move towards value-based procurement is an essential step in evolving healthcare delivery. With the adoption of innovative procurement solutions and technologies, the NHS is well-positioned to achieve its goals of providing superior, patient-centered care. The current delay in implementing VBP serves as a reminder of the need for all stakeholders in healthcare procurement to intensify their efforts and ensure the NHS’s capabilities to deliver quality care promptly.

For those interested in learning more about Vamstar and its offerings, our team is ready to provide detailed information and discuss how we can support your procurement needs. Further contact details are available below.

Leading pharmaceutical companies are increasingly focusing on global health initiatives, which has led to a rise in procurement through tenders and long-term agreements (LTAs) by Intergovernmental Organizations (IGOs) and Non-Governmental Organizations (NGOs).

In 2023, the total value of pharmaceuticals and medical supplies distributed by these entities is estimated at US$ 21.3 billion, with a significant portion allocated to vaccines, medical supplies, and diagnostics. Pharmaceuticals alone account for about US$ 4.7 billion of this total.

The Covid-19 pandemic caused a noticeable surge in healthcare spending by NGOs and IGOs in 2021, particularly in diagnostics and vaccines. Although the pharmaceutical sector experienced a decline during this period, it has been witnessing a notable upward trend since 2022, with an average year-over-year growth of over 11%.

This trend underscores the growing significance of global health teams within pharmaceutical companies.

These teams are becoming increasingly important due to various factors:

1. Shifting Disease Landscape: There’s a growing prevalence of neglected tropical diseases and infectious diseases in low- and middle-income countries (LMICs), requiring innovative approaches and partnerships for drug development.

2. Equity and Access: Heightened awareness of healthcare inequities in LMICs is pressuring pharmaceutical companies to improve access to essential medicines. Global health teams are pivotal in addressing these challenges by developing sustainable distribution models and navigating complex healthcare systems.

3. Emerging Markets: LMICs are emerging as significant markets for pharmaceuticals. Global health teams are key in helping companies understand and penetrate these markets.

4. Pandemic Preparedness: The COVID-19 pandemic highlighted the need for improved outbreak preparedness. Teams with expertise in public health and vaccine development are valuable for future pandemic response strategies.

5. Regulatory Landscape: As governments and international bodies implement policies to enhance medicine accessibility in LMICs, global health teams are crucial for ensuring compliance and navigating these regulations.

Companies are recognising that strong global health programs not only fulfill social responsibilities but also attract consumers and investors. These programs are focused on making medicines more affordable and accessible in LMICs through various initiatives.

Industry Response Includes:

• Establishing dedicated global health units.
• Engaging in public-private partnerships.
• Exploring innovative financing models.
• Investing in local capacity building.
• Developing medicines for neglected tropical diseases (NTDs).

Challenges and Opportunities:

Despite their importance, global health teams face challenges such as limited resources and the need to balance commercial objectives with social impact. However, the opportunities for significant social impact, market access, and long-term value creation are substantial. These teams play a crucial role in strengthening healthcare systems, advocating for policy change, and demonstrating the value of global health initiatives.

One major challenge is the lack of transparency and market intelligence in the sector, where a large portion of the market remains non-tender based and procurement is often local and in partnership with governments. Vamstar is addressing this challenge by combining AI-based data scraping with subject matter expertise to provide ATC class-level market insights, which are vital for shaping global health strategies in the pharmaceutical industry.

The realm of interventional cardiology (IC) stands at the cusp of a transformative era, marked by rapid technological advancements, evolving clinical practices, and an ever-expanding scope of therapeutic applications. The Global Interventional Cardiology Market Report offers an unparalleled deep dive into this dynamic field.

This exhaustive analysis covers the spectrum of IC techniques, devices, market trends, and growth prospects, positioning itself as an indispensable resource for a diverse audience including medical professionals, commercial teams, researchers, investors, and stakeholders.

The report draws upon a rich tapestry of sources to ensure a robust and comprehensive market analysis. Engagements with key stakeholders across the spectrum, ranging from IC device suppliers and policy experts to clinicians and hospital executives — provide foundational insights.

The research is further bolstered by an analysis of financial reports, product brochures, technical literature, and a decade’s worth of in-house data leverage through Vamstar’s AI, ensuring a multi-faceted perspective on the industry.

1. Comprehensive Market Overview: Provides a detailed examination of the interventional cardiology (IC) market, including an extensive review of IC techniques, devices, and current market trends. This feature ensures readers gain a thorough understanding of the field.

2. In-depth Analysis of Devices: Each device category, from aspiration catheters to vascular closure devices, is analysed to offer insights into their applications, technological advancements, and market positioning.

3. Robust Research Methodology: Compiled using a mix of primary interviews with industry stakeholders and secondary research, including financial reports, public sources, and technical literature, ensuring a well-rounded perspective on the IC market.

4. Detailed Forecasting: Utilises a dual approach combining ‘bottom-up’ and ‘top-down’ analyses for market estimates, offering precise forecasts from 2024 to 2028. This predictive insight is crucial for strategic planning and investment decisions.

5. Global Coverage with Regional Insights: Segments the market into key geographical regions, providing specific insights into North America, South America, Europe, the Middle East and Africa, and Asia Pacific. This allows for a granular understanding of regional dynamics and opportunities.

1. Strategic Decision Support: Empowers medical professionals, commercial teams, investors, and stakeholders with actionable insights and comprehensive market intelligence for informed decision-making.

2. Commercial Guidance: Offers investors and commercial teams data-driven insights into growth prospects, technological trends, and market dynamics, aiding in the identification of lucrative investment opportunities and potential areas for expansion.

3. Competitive Edge: Equips device manufacturers and suppliers with a detailed understanding of the competitive landscape, helping them to strategise effectively and stay ahead in the market.

4. Policy and Procurement Planning: Assists policy experts, procurement specialists, and hospital executives in understanding current trends and future directions of the IC market, facilitating better planning and procurement strategies.

5. Educational Value: Serves as a valuable educational resource for researchers, clinicians, and medical professionals seeking to deepen their knowledge of interventional cardiology, its techniques, and its devices.

The Global Interventional Cardiology Market Report emerges as a beacon for those navigating the complex waters of the IC industry. Its in-depth analysis, comprehensive market insights, and forward-looking projections equip stakeholders with the knowledge to make informed decisions, harness opportunities, and face challenges head-on in this rapidly evolving field.